Every Form 4 that Colgate-Palmolive Company (CL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CL filings page.
Colgate-Palmolive Chief Human Resources Officer Sally Massey reported an option exercise and related share sale. On February 5, 2026, she exercised stock options for 15,851 shares of common stock at $76.41 per share, awarded under the company’s incentive compensation plan.
That same day, she sold 15,851 shares of common stock at a weighted average price of $95.0279, with part of the proceeds used to pay the option exercise price and related tax withholding. After these transactions, she directly owned 13,751 shares of Colgate-Palmolive common stock and held an additional 8,111 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Financial Officer, Stanley J. Sutula III, exercised stock options and sold shares in a planned transaction. On February 4, 2026, he exercised 97,843 stock options at an exercise price of $81.78 per share under the company’s incentive compensation plan.
That same day, he sold 97,843 shares of common stock at a weighted average price of $94.2662 per share, with a portion of the proceeds delivered to Colgate-Palmolive to cover the option exercise price and related tax withholding. After these transactions, he directly owned 55,310 common shares and indirectly held 328 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Legal Officer and Secretary, Jennifer Daniels, reported an option exercise and share sale. On February 4, 2026, she exercised stock options for 22,000 shares of common stock at $72.29 per share under the company’s incentive plan, increasing her direct holdings to 98,406 shares.
That same day, she sold 22,000 shares of common stock at a weighted average price of $94.3363 per share in multiple transactions, leaving 76,406 shares held directly. A footnote explains that part of the sale proceeds went to Colgate-Palmolive to cover the option exercise price and related tax withholding. She also holds 1,837 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported a sale of common stock. On February 4, 2026, he sold 45,568 shares of Colgate-Palmolive common stock at a weighted average price of $93.9145 per share, in multiple transactions within a stated price range.
After this sale, Wallace directly owned 293,188 common shares. He also reported indirect ownership of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.
Colgate-Palmolive Company director reports stock acquisition under compensation plan
A director of Colgate-Palmolive Company reported acquiring 238 shares of common stock on 01/02/2026 at a price of $78.66 per share. The filing notes this represents a portion of the director’s annual cash retainer that was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors.
Following this transaction, the director beneficially owns 5,313 shares of Colgate-Palmolive common stock directly and 36 shares indirectly through a family trust.
Colgate-Palmolive Company director reports a small equity transaction. A board member acquired 333 shares of Colgate-Palmolive common stock on 01/02/2026 at a price of $78.66 per share, according to a Form 4 filing. After this transaction, the director beneficially owns 39,648 shares held directly.
The filing explains that the transaction reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The form is signed by an attorney-in-fact on 01/06/2026, indicating the report was made on the director’s behalf.
Colgate-Palmolive Company director reports deferred stock award
A director of Colgate-Palmolive Company reported acquiring 301 shares of common stock on 01/02/2026 at a price of $78.66 per share. According to the footnote, this reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, rather than a market purchase for cash.
Following this transaction, the director beneficially owns 37,195 shares directly and 4,719 shares indirectly through a trust. The filing confirms the individual’s status as a director and that the report is filed for one reporting person.
Colgate-Palmolive Company Chairman, President & CEO and director reported a routine tax-related share withholding. On 12/03/2025, the executive disposed of 1,307 shares of common stock at $78.2 per share, coded as an "F" transaction, meaning shares were withheld to cover Medicare and income tax owed on previously granted restricted stock units. The executive continues to hold those restricted stock units, reduced only by the shares used for required tax withholding.
After this transaction, the executive beneficially owns 338,756 shares directly. Additional indirect holdings include 53,923 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.
Colgate-Palmolive Company officer reports small share withholding for taxes. A company officer serving as COO, Eur., APac, Afr Eur, Skin reported a Form 4 transaction involving Colgate-Palmolive common stock. On 12/03/2025, 221 shares of common stock were disposed of at $78.2 per share, coded as transaction type F, which represents shares withheld to cover Medicare and income tax on previously granted restricted stock units under the company’s incentive compensation plan.
After this tax withholding, the officer beneficially owns 10,415 shares directly, 4,538 shares indirectly through the issuer's 401(k) plan trustee, and 60,745 shares indirectly through a trust. The filing notes that the officer continues to hold the original restricted stock units granted, reduced only by the amount required for this tax withholding.
Colgate-Palmolive Company’s Chief Financial Officer, reported on a Form 4 that shares of company stock were withheld to cover taxes on previously granted restricted stock units. On 12/03/2025, 385 shares of common stock were disposed of at a price of $78.2 per share through tax withholding, coded as transaction type "F," which indicates payment of tax liability from equity awards.
After this transaction, the officer beneficially owns 55,310 shares of Colgate-Palmolive common stock directly, and an additional 326 shares indirectly through the issuer’s 401(k) plan trustee. The filing clarifies that the underlying restricted stock units remain held by the officer, reduced only by the amount required for Medicare and income tax withholding.
Colgate-Palmolive Company executive Kristine Hutchinson, EVP and Controller, reported a small tax-related stock transaction. On 12/03/2025, 41 shares of Colgate-Palmolive common stock were disposed of at $78.2 per share under transaction code "F," which indicates shares were withheld to cover taxes on previously granted restricted stock units.
After this transaction, Hutchinson beneficially owns 11,879 shares of Colgate-Palmolive common stock directly and 8,497 shares indirectly through the issuer's 401(k) plan trustee. The explanation notes that she continues to hold the original restricted stock units, reduced only by the number of shares withheld to satisfy Medicare and income tax obligations.
Colgate-Palmolive Company’s Chief Growth Officer reported a small share transaction involving company stock. On 12/03/2025, 156 shares of Colgate-Palmolive common stock were disposed of at $78.2 per share in a transaction coded “F,” which indicates shares were withheld by the company to cover Medicare and income tax obligations tied to previously granted restricted stock units. After this tax withholding, the officer beneficially owns 17,645 shares directly and 5,416 shares indirectly through the issuer’s 401(k) plan trustee. The underlying restricted stock units remain in place, reduced only by the shares used for required tax withholding.
Colgate-Palmolive (CL) reported a routine insider tax-withholding transaction by its Chief Legal Officer and Secretary. On 12/03/2025, the executive had 213 shares of common stock withheld at a price of $78.2 per share, coded as an "F" transaction, which indicates shares were withheld to cover Medicare and income tax obligations on previously granted restricted stock units under the company’s incentive compensation plan.
After this non-open-market transaction, the executive beneficially owns 76,406 shares of Colgate-Palmolive common stock directly and an additional 1,825 shares indirectly through the issuer's 401(k) plan trustee. The filing notes that the restricted stock units themselves continue to be held, reduced only by the amount of shares withheld for taxes.
Colgate-Palmolive Company (CL) reported an insider stock transaction by its Chief Human Resources Officer. On 11/21/2025, the officer sold 1,237 shares of Colgate-Palmolive common stock at a price of $80.89 per share. After this sale, the officer beneficially owned 13,751 shares directly and 8,058 shares indirectly through the issuer's 401(k) plan trustee. The filing was made on a Form 4, which discloses changes in insider ownership.